CardioVia Selected as a Late-Breaking Clinical Trial at HRS

May 2022

CardioVia’s ViaOne Selected as a Late-Breaking Clinical Trial at the Heart Rhythm Society

CardioVia’s First-in-Human clinical study of ViaOne was selected as a Late Breaking Clinical Trial at the Heart Rhythm Society (HRS) Annual Scientific Sessions. This recognition underscored the significance of ViaOne in addressing one of the greatest unmet needs in electrophysiology.

The Heart Rhythm Society clinical trial presentation highlighted the results of CardioVia’s pioneering work in minimally invasive epicardial access. ViaOne™ introduces a new method of controlled heart-surface access using a blunt-tip concealed needle and bio-impedance navigation system—technologies designed to reduce the risks traditionally associated with pericardial entry.

Selection as a Heart Rhythm Society clinical trial reflects the strong interest among electrophysiologists in safer, more predictable access solutions for complex cardiac arrhythmia procedures. The ViaOne study demonstrated the potential for improved procedural outcomes and fewer complications, positioning CardioVia’s technology as a transformative tool in cardiac interventions.

CardioVia continues to build on this early clinical success through ongoing collaborations with leading medical centers worldwide.